Industry Insight from Reuters Events, a part of Thomson Reuters. U.S. grid owners are investing in cost-efficient grid enhancements and virtual power plant schemes to help meet soaring demand but ...
BOSTON, MA—Baroreflex activation therapy (BAT) delivered by the Barostim implant (CVRx) is associated with a range of benefits in patients who have advanced heart failure with reduced ejection ...
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...
Hosted on MSN
Inside the world’s most advanced off-grid mansion
In this video, we spend 96 hours in a fully sustainable, off-grid luxury home surrounded by the ocean. Join us as we explore the beautiful environment and experience life in this unique setting.
Modeling energy growth associated with data centers and smart integration through load flexibility and real-time coordination unlocks a new frontier in grid modernization. Oak Ridge National ...
The Electric Power Research Institute quizzed large language models’ ability to handle issues confronting U.S. power systems. It didn’t go well. Grid operators don’t have to fear losing their control ...
SparkCharge has partnered with the Massachusetts Clean Energy Center (MassCEC) and Zipcar to launch the Northeast’s first off‑grid, mobile DC fast‑charging hub for shared EVs. The goal is to bring ...
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the ...
Positive Grid has announced its Spark NEO Core, the newest member of the Spark NEO family of smart guitar headphones. These wired headphones integrate a Spark guitar amp in a lightweight, ergonomic ...
It’s been a minute since I’ve used a Positive Grid product, and the one I have used, I still use today: the Spark MINI. So when the company announced the Spark LINK XLR, I emailed them and asked if I ...
Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results